2305770-44-7
2305770-44-7
Chemical Structure
Biological Activity: Mibavademab (REGN4461) is a LEPR agonist monoclonal antibody. Mibavademab activates leptin receptor (leptin receptor) and LEPR signaling, enhances leptin (leptin)-induced STAT3 activity without competing with leptin binding, and binds with high affinity to the human LEPR extracellular domain. Mibavademab can be used for research on leptin deficiency[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mibavademab | ≥99.0% | Mibavademab (REGN4461) is a LEPR agonist monoclonal antibody. Mibavademab activates leptin receptor (leptin receptor) and LEPR signaling, enhances leptin (leptin)-induced STAT3 activity without competing with leptin binding, and binds with high affinity to the human LEPR extracellular domain. Mibavademab can be used for research on leptin deficiency. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Van der Borght E, et al. Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date. Frontiers in endocrinology. 2026;17:1815903.
- [2]. Altarejos JY, et al. Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency. Science translational medicine. 2023 Nov 22;15(723):eadd4897.
